Trial Profile

Study of AlucentNVS in Australia

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 18 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Peripheral vascular disorder therapeutics Alucent Biomedical (Primary)
Indications Arteriovenous fistula; Peripheral vascular disorders
Focus Therapeutic Use
Sponsors Alucent Biomedical

Most Recent Events

18 Aug 2023 New trial record
02 Aug 2023 According to a Alucent Biomedical media release, enrollment in this study is expected to conclude by the end of 2023.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com